

From: dph.immunizations@ct.gov <noreply@everbridge.net>

Sent: Monday, November 14, 2022 10:26 AM

Subject: New Pfizer Single Dose Vials and COVID-19 Vaccine Updates



DEPARTMENT OF PUBLIC HEALTH

November 14, 2022

Dear Connecticut COVID-19 Vaccine Providers,

This communication is being sent to all key contacts at provider organizations administering COVID-19 vaccine— please read this message in its entirety. Please feel free to share it with others in your organization who may benefit from the update. Note that all our communications are archived on our [web site](#).

Pfizer updated (bivalent) COVID-19 vaccine for people 12 years of age or older is now available to order in a new single-dose vial presentation. This vial presentation is in response to widespread requests from vaccine administration partners for the greater flexibility this presentation provides. We expect to have a limited initial supply of this new vial presentation but will continue to have sufficient supply of the multi-dose vial presentation of the updated (bivalent) Pfizer vaccine for people 12 years of age or older.

Providers who want to request the new single-dose presentation should place an order using the standard weekly ordering practice through the [submissions portal](#).

Providers should read the following information before placing an order:

- **Quick Facts: Single-Dose Vial Pfizer Bivalent Booster (Ages 12+)**
 - NDC: 59267-1404-02
 - Configuration: 10 single-dose vials/carton
 - Minimum quantity per order: 50 doses
 - Maximum quantity per order: 150 doses
 - Product dimensions: 1.457 in length x 1.535 in width x 3.504 in height
 - Storage and handling: Same as other Pfizer tris products (e.g., store at ultra-low temperature until expiry, may refrigerate up to 10 weeks within expiry period)
 - No ancillary kits included with single-dose vial orders. Single-dose vials do not require the use of low-dead-volume (LDV) syringes. If supply concerns exist, it is recommended that providers use surplus appropriate onsite materials for vaccine administration.
- Depending on order volume, priority for single-dose vials may be given to providers that may not have the capacity or demand to keep multi-dose vials of COVID-19 vaccine on hand. Or if use of the single-dose vials provides expanded access at doctors' offices or community health centers that have consistently low or irregular patient traffic and/or might not otherwise offer the COVID-19 vaccine.

New CDC Webinar - Recommendations for Bivalent COVID-19 Booster Dose

CDC's [COVID-19 Vaccine Webinars](#) are brief presentations designed to provide immunization providers with the most up-to-date information on the vaccines used to fight the virus that causes COVID-19. The new [Recommendations for Bivalent COVID-19 Booster Doses](#) course discusses recommendations for a bivalent COVID-19 booster dose, the interim COVID-19 immunization schedule to date, COVID-19 vaccine products, and recommended actions for addressing bivalent and monovalent COVID-19 vaccine administration errors.

COVID-19 Vaccine Commercialization

Some of you may have heard in the news that the U.S. Government (USG) is working on a plan to commercialize COVID-19 vaccines. See the White House factsheet [here](#). While we don't have an official timeline or a finalized plan yet there are some key assumptions that providers can start to plan for.

- Once COVID-19 vaccines are commercialized they will no longer be supplied by the USG at no cost through the COVID-19 vaccine program. However, COVID-19 vaccines will be available to order like other routine vaccines:
 - 1) for children (under 19) vaccines will be available through the Vaccines for Children (VFC) program
 - 2) for adults (19+) vaccines will be available for purchase on the commercial market and the USG is exploring an expanded Vaccines for Adults (VFA) program to supply vaccine for the under- and uninsured.
- Vaccine administration reimbursement rates are expected to change once the vaccine is commercialized and there is an end of the public health emergency (PHE) declaration.
- No-cost ancillary supply kits will cease when the USG no longer supplies the vaccine.

The plan for commercialization involves multiple agencies like Centers for Medicare and Medicaid Services, Centers for Disease Control and Prevention, and USG. CT DPH will share information as it becomes available.

Resource:

<https://aspe.hhs.gov/sites/default/files/documents/1072f5093254224ac902ca395387085c/cover-age-considerations-covid-19.pdf>

Thank you for all your ongoing work and support of our COVID-19 vaccine roll-out in Connecticut.

For the CT DPH Immunization Program, visit: [Contact Us](#).

For the COVID-19 webpage, visit: [COVID-19 Vaccine Program](#).

If you would like to subscribe to receive these communications, please complete [this form](#). If you would like to unsubscribe from receiving these communications, please complete [this form](#).